Cardiometabolic and Lipids Strategies for Endocrinologists-Non alcoholic Fatty Liver guideline

Video Transcription

Video Summary

In the video, a panel of experts discusses the management of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in patients with diabetes and obesity. The experts present the newly released guidelines by the American College of Endocrinology (ACE) on the diagnosis and management of NAFLD and NASH. They highlight the high prevalence of NAFLD in individuals with type 2 diabetes and the increased risk of cardiovascular disease and liver-related complications associated with NAFLD. They discuss the importance of early diagnosis and risk stratification in order to identify individuals at high risk for fibrosis. The experts emphasize lifestyle modifications, such as a Mediterranean diet and exercise, as key strategies for management. They also discuss the use of pharmacotherapy, including pioglitazone and GLP-1 receptor agonists, for the treatment of NASH in patients with and without diabetes. The panel also addresses the importance of addressing comorbidities such as hypertension and dyslipidemia in patients with NAFLD. They highlight the need for regular screening, monitoring, and appropriate use of medications to prevent disease progression and reduce liver-related complications. The session provides valuable insights into the diagnosis and management of NAFLD and NASH, emphasizing the importance of early intervention and a multidisciplinary approach for optimal patient care.

Keywords

non-alcoholic fatty liver disease

non-alcoholic steatohepatitis

diabetes

obesity

American College of Endocrinology

lifestyle modifications

Mediterranean diet

pharmacotherapy

fibrosis

cardiovascular disease

early intervention